NASDAQ:PROK ProKidney Q4 2025 Earnings Report $1.65 -0.18 (-9.84%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$1.64 -0.01 (-0.91%) As of 04:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast ProKidney EPS ResultsActual EPS-$0.14Consensus EPS -$0.16Beat/MissBeat by +$0.02One Year Ago EPSN/AProKidney Revenue ResultsActual Revenue$0.23 millionExpected Revenue$0.00 millionBeat/MissBeat by +$229.00 thousandYoY Revenue GrowthN/AProKidney Announcement DetailsQuarterQ4 2025Date3/18/2026TimeBefore Market OpensConference Call DateWednesday, March 18, 2026Conference Call Time7:00AM ETUpcoming EarningsProKidney's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) ProKidney Earnings HeadlinesProKidney (PROK) Stock Forecast & Price TargetSeptember 19, 2026 | investing.comProKidney (PROK) Nears A Pivotal Kidney Therapy VerdictSeptember 11, 2026 | finance.yahoo.comNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to build its replacement is reportedly headed to a tiny firm a fraction of SpaceX's size, one NASA has quietly funded for five years. History shows these NASA announcements can move fast: Intuitive Machines jumped 66% in a day, Momentus soared 155%, and Sidus Space climbed 180% after landing subcontractor roles. | Behind the Markets (Ad)ProKidney Corp. (PROK) Options Chain - Yahoo FinanceAugust 26, 2026 | finance.yahoo.comProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)August 14, 2026 | seekingalpha.comProKidney (PROK) Receives a Hold from Morgan StanleyAugust 14, 2026 | theglobeandmail.comSee More ProKidney Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ProKidney? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProKidney and other key companies, straight to your email. Email Address About ProKidneyProKidney (NASDAQ:PROK) Corporation (NASDAQ: PROK) is a biotechnology company focused on developing cell therapies for chronic kidney disease (CKD). Its lead investigational product, rilparencel, is an autologous cell therapy designed to use a patient’s own kidney cells to support kidney function and potentially delay or reduce the need for dialysis or kidney transplantation. Rilparencel, formerly known as REACT, is being evaluated as a minimally invasive treatment intended for patients with advanced CKD. The company’s approach involves collecting a small sample of kidney tissue, processing the cells, and reinjecting them into the patient’s kidneys. ProKidney has conducted clinical development programs in the United States and other regions to assess the therapy’s safety and effectiveness. ProKidney was founded in 2015 and became a publicly traded company in 2022 through a business combination with Social Capital Suvretta Holdings Corp. III. The company is headquartered in Winston-Salem, North Carolina, and remains focused on advancing rilparencel and other potential cell-based treatments for kidney disease.View ProKidney ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
